U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/22971699; http://www.ncbi.nlm.nih.gov/pubmed/23318685

Peginesatide (trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. Peginesatide is a synthetic peptide, attached to polyethylene glycol ("PEGylated"). It mimics the structure of erythropoietin, the human glycoprotein which promotes red blood cell development. Peginesatide binds to and activates the human erythropoietin receptor and stimulates erythropoiesis in human red cell precursors in vitro.

CNS Activity

Curator's Comment: In rats there was no evidence that peginesatide distributes beyond the blood-brain barrier

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P19235
Gene ID: 2057.0
Gene Symbol: EPOR
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
OMONTYS

Approved Use

Indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.

Launch Date

2012
PubMed

PubMed

TitleDatePubMed
Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.
2009 Nov
Detection of peginesatide in equine serum using liquid chromatography-tandem mass spectrometry for doping control purposes.
2012
Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis.
2013
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: intravenous or subcutaneous injection
Initiate OMONTYS treatment when the hemoglobin level is less than 10 g/dL. The recommended starting dose for the treatment of anemia in patients who are not currently treated with an ESA is 0.04 mg/kg body weight administered as a single intravenous or subcutaneous injection once monthly.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Name Type Language
PEGINESATIDE ACETATE
ORANGE BOOK   USAN   WHO-DD  
USAN  
Official Name English
AF37702 ACETATE
Code English
PEGINESATIDE ACETATE [ORANGE BOOK]
Common Name English
HEMATIDE ACETATE
Brand Name English
Peginesatide acetate [WHO-DD]
Common Name English
PEGINESATIDE ACETATE [USAN]
Common Name English
AF-37702 ACETATE
Code English
AF 37702 ACETATE
Code English
Code System Code Type Description
USAN
ZZ-99
Created by admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
PRIMARY
RXCUI
1248797
Created by admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
PRIMARY RxNorm
FDA UNII
44STI720CW
Created by admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID201027899
Created by admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL1963684
Created by admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
PRIMARY
CAS
1185870-58-9
Created by admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
PRIMARY
DRUG BANK
DBSALT000136
Created by admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
PRIMARY
NCI_THESAURUS
C166719
Created by admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
PRIMARY